Principal Investigator
Jonathan Trent
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20241323
Clinical Trial Summary
A Phase 1a/1b Study of the Safety, Pharmacokinetics, and Antitumor Activity of the Oral Menin Inhibitor Ziftomenib in Combination with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors (GIST) After Imatinib Failure (KOMET-015)
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Bone and Soft Tissue Cancers
Contact Information
Phone Number
+1 (954) 8177628